Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Annals of Hematology, Springer Science and Business Media LLC, Vol. 86, No. 8 ( 2007-8), p. 565-568
    Type of Medium: Online Resource
    ISSN: 0939-5555 , 1432-0584
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2007
    detail.hit.zdb_id: 1458429-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Photochemistry and Photobiology, Wiley, Vol. 71, No. 6 ( 2000), p. 737-
    Type of Medium: Online Resource
    ISSN: 0031-8655
    RVK:
    Language: English
    Publisher: Wiley
    Publication Date: 2000
    detail.hit.zdb_id: 2048860-9
    SSG: 12
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Leukemia & Lymphoma, Informa UK Limited, Vol. 14, No. 5-6 ( 1994-01), p. 483-489
    Type of Medium: Online Resource
    ISSN: 1042-8194 , 1029-2403
    Language: English
    Publisher: Informa UK Limited
    Publication Date: 1994
    detail.hit.zdb_id: 2030637-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    In: European Journal of Haematology, Wiley, Vol. 93, No. 2 ( 2014-08), p. 129-136
    Abstract: In primary cutaneous B‐cell lymphomas ( PCBCL ), radiotherapy – or surgery in a minority of cases – is the first‐line treatment in follicle center lymphoma ( PCFCL ) and marginal zone B‐cell lymphoma ( PCMZL ). Conversely, patients with multifocal skin involvement or relapsed/refractory disease deserve a systemic chemotherapy. In diffuse large B‐cell lymphoma, leg type ( PCLBCL‐LT ), due its poorer outcome, cyclophosphamide, doxorubicin, vincristine, and prednisone ( CHOP )‐like regimens are the most commonly used frontline, although hard to propose in elderly patients. In this regard, the association of rituximab ( R ) and pegylated liposomal doxorubicin ( PLD ) can be considered a promising, alternative approach. Aims Based on the favorable results reported with R and PLD in several recent trials, we decided to test efficacy and safety of this combination. Methods Twelve patients with PCBCL were treated with R plus PLD , and 7 had relapsed disease. Treatment plan consisted of 2 monthly cycles of R 375 mg/m 2 and PLD 20 mg/m 2 day 1;15, followed (in responders) by two cycles given only at day 1. All patients received prophylactic pyridoxine to prevent palmar‐plantar erythrodysesthesia ( PPE ). Results Ten of 12 patients had a response (eight complete; two partial), remarkably 2/3 with PCLBCL‐LT . Two patients did not respond (one progressive disease, PD , and one stable disease). Three patients died after a median follow‐up of 56 months, two patients due to PD , and 1 due to a second neoplasm. Two out of 10 responders relapsed after 31 and 32 months, respectively. Hematological toxicity was negligible (one case of grade 2 neutropenia), as well as extra‐hematological toxicity (two cases of grade 2 PPE ). Conclusions These preliminary data suggest that R‐PLD is effective and well tolerated in all subsets of PCBCL and may be offered frontline in indolent cases unsuitable for radiotherapy or surgery as well as in more aggressive cases with contraindications to CHOP ‐like regimens.
    Type of Medium: Online Resource
    ISSN: 0902-4441 , 1600-0609
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2014
    detail.hit.zdb_id: 2027114-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 108, No. 11 ( 2006-11-16), p. 4685-4685
    Abstract: The majority of patients (pts) with diffuse large-B cell lymphoma (DLBCL) are elderly and may have limited tolerance to chemotherapy due to concomitant diseases. Non-pegylated liposomal doxorubicin has an improved therapeutic index in comparison to doxorubicin, resulting in less myelosuppression, lower GI toxicity and reduced risk of cardiotoxicity at dose level equivalent to standard formulations of doxorubicin. The aim of this study was to assess the efficacy and feasibility of the combination of cyclophosphamide, vincristine, prednisone and liposomal doxorubicin with rituximab every three weeks (R-COMP21) in DLBCL elderly pts with concomitant disease or relapsed pts pre-treated with anthracyclines containing regimens. We analysed twenty-five not consecutive pts from June 2003 to December 2005 according to following negative characteristics: 5 pts over 75 years (20%), 8 pts pretreated with anthracyclines (32%), 12 pts (48%) with heart disease (5 ischemic, 2 hypokinetic and 5 hypertensive cardiomiopathy). Median age was 71 years (range 54–76). 3 pts were stage I, 6 stage II, 5 stage III and 11 stage IV. According to IPI score 8 pts were low risk, 9 low-intermediate, 7 intermediate-high and 1 high risk. The median left ventricular ejection fraction (LVEF) at diagnosis was 59% (range 42%–75%). All pts were evaluable for response to therapy: 18 (72%) obtained a complete remission (62,5% in pre-treated pts), 5 (20%) obtained a partial remission with an overall response rate of 92%. Two pts did not respond to therapy. After a total of 126 cycles we observed three toxic event (congestive heart failure, stroke and gastrointestinal bleeding). No significant hematological toxicity was recorded. Four percent of cycles were delayed. Median final LVEF was 57% (47%–65%). All pts but one had no change in LVEF, one patient developed a congestive heart failure resolved with medical therapy: he was withdrawn due to decrease of LVEF. After a median observation period of 2 years (range 2–68 months), 71% of pts are alive, five pts died two due toxicity and three due to progressive disease. We compared these outcomes with an historical control of 26 aggressive NHL pts treated from February 2001 to June 2005; these pts received no doxorubicin (10 pts) or a mitoxantrone-based scheme devised for elderly (16 pts) due to age or concomitant disease. Case matching was performed with respect to clinical stage, IPI, sex, symptoms, bulky disease, LVEF, with the exception of age (which was greater in control group: median 76 vs 71 p=.001) and heart disease which was more frequent in experimental group (48% vs 31% p=.02). Allowing for the limitations of studies using historic controls, the R-COMP regimen was associated with higher CR (72% vs 42%) and OS rates (71% vs 42%). These results did not change when only pts treated with rituximab are considered. We conclude that the general tolerability and the low incidence of cardiac events of liposomal doxorubicin warrants further studies in a subset of pts with concomitant disease limiting the use of conventional anthracyclines.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2006
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 4995-4995
    Abstract: Abstract 4995 Background The response evaluation is performed by computed tomography (CT) as a standard tool in DLBCL. The introduction the FDG-PET performed for post treatment response assessment of aggressive Non Hodgkin's Lymphoma (NHL) is advised by the Revised International Workshop Criteria (IWC). We explored the predictive value by FDG-PET scan performed at the end of therapy in patients (pts) with DLBCL treated with rituximab-containing regimens . Patients From 2003 at 2008 were included 86 pts with DLBCL treated with Rituximab and CHOP or CHOP-like regimens. The FDG-PET and CT was mandatory at baseline and at the end of therapy to include pts in the study. We evaluated the progression free survival (PFS) of pts starting from the time of diagnosis to early relapse or disease progression or last follow-up. Results Median age was 60 years (28-78), 40 pts were female and 46 male, 38 pts presented stage I-II and 48 stage III-IV. The International Prognostic Index (IPI) was low in 20% of pts, low-intermediate in 50%, intermediate-high in 28% and high risk in 2%; bulky was reported in 24 pts. Seventy-seven pts attained complete remission (CR) (89%), 8 pts (9%) partial remission (PR) and 1 pts progression disease (2%). The FDG-PET and CT performed at the end of therapy were both negative in 61 pts (71%); both positive in 9 pts (10%). In the remaining pts the FDG-PET and CT scan performed post therapy were discordant in particular in 13 pts (15%) FDG-PET was negative and CT was positive and in 3 pts (4%) FDG-PET was positive and CT was negative. Thus the positive predictive value of a FDG-PET at the end of therapy was 63% and the negative predictive value was 87%. The sensitivity and specificity of FDG-PET at the end of therapy were 41% and 94% respectively. The positive predictive value and the negative predictive value of a CT at the end of therapy were 43% and 87% respectively. The sensitivity of CT at the end of therapy was 53% and the specificity was 83%. Fifthteen out seventy-four patients (20%) with negative FDG-PET progress or relapse within 6 months (median 4 months). Five out twenty (25%) FDG-PET negative bulky disease pts progress or relapse within 6 months moreover four out seventeen (24%) CT negative bulky disease pts progress or relapse. With a median follow-up of 20 months (range 7-83) the overall survival was 86%, and with a median follow-up of 15 months (range 2-78) the PFS was 76%. Conclusions FDG-PET shows an high specificity but a very low sensibility in DLBCL. An high rate of false negative FDG-PET was observed in bulky disease patients. We have observed that pts with negative FDG-PET presented a rapid relapse or progression therefore we can consider that probably in non-Hodgkin's lymphoma PET should be performed after four months from the end of therapy to reduce false negative. Obviously larger study are needed but at the moment CT remain the most sensible instrument to define CR in non-Hodgkin's lymphoma. Disclosures Vitolo: Roche:.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    In: Blood, American Society of Hematology, Vol. 114, No. 22 ( 2009-11-20), p. 5126-5126
    Abstract: Abstract 5126 Introdution Systemic sclerosis (SSc) involves the microcirculation, the immune system, and the connective tissue eventually leading to fibrosis. Vascular dysfunction is one of the earliest events in SSc pathogenesis: endothelial damage leads to a dysregulation of angiogenesis and a loss of capillaries. The consequent chronic ischemia provokes a diffuse sufference of the tissues with formation of ulcers. We analyzed BM biopsies in a series of patients undergoing HSCT in our Centre for severe, progressive SSc in order to clarify the association between modification bone marrow angiogenesis and clinical features of this disease. Materials and Methods The main clinical feature of the patients are following: modified Rodnan Skin Score was more than 8 in four patients; nailfold videocapillaroscopy was active in three patients; pulmonary arterial hypertension was upper limit only in two patients; carbon monoxide diffusing capacity was more than 40% in all the patients; high resolution computed tomography showed fibrosis or ground glass lesions in all the patients; topoisomerase I and antinuclear antibody was positive in all the patients. Only one patient showed arrhythmia. Eight SSc bone marrow biopsies were studied, compared with five bone marrow biopsies of non malignant controls. To evaluate angiogenesis, following monoclonal antibodies (MoAb) were used: VEGF, KDR, MMP-9, CD34. Bone marrow fibrosis was evaluated by silver impregnation for reticulum. To identify BM microvessel, anti-CD34 was used. Sections were observed at 400x magnification by two different blinded observers. To calculate the number of vessels, vascular mean area expressed in mm2, vascular percent mean area, perimeter and MVD, a multiparametric, semi-automatic computerized imagine analysis was employed. For each section, we evaluated eight consecutive areas and each area was 16001,92 mm2 (total area was 128015,36 mm2). The VEGF, MMP-9, KDR expression was evaluated as percentage of positive cells in a total of eight consecutive areas at 400x magnification. Results All patients showed a mean cellularity of 40% (SD 5.24, range 30-45%). In four patients bone marrow fibrosis was detected: two patients were classified as I° grade and two as II°grade. The bone marrow biopsy specimens from patients with SSc show a substantial reduction in vascularity. A multiparametric computerized analysis demonstrated significantly reduction of MVD in SSc cases. The mean MVD in SSc bone marrow was 712,63 (SD 392.03, range 124,98-1312,34) whereas in control specimens it was 1364,58 (SD 44.20, range 1312,34-1402,14). The mean number of vessels (p0.004) and percent vascular mean area are lower in sclerosis than controls (p0.0009). A significant increased expression of VEGF was observed. The median VEGF rate was 48,75 (range 30-85%) with expression ≥ 50% in half patients and in two patients with advanced SSc this expression was more than 70%. KDR expression was significantly lower in SSc bone marrow than in controls (p=0,003). The median KDR rate was 13,25% (range 1-40%) and 42% (range 40-45%) in sclerosis and controls respectively. In all cases the expression of MMP-9 was significantly lower than controls (p=0,0009) with median rate of 13,06% (range 1-25%) while median expression in controls was 30% (range 20-40%). Discussion We demonstrated in patient with SSc a reduction of bone marrow vascularity despite the stricking increase of a number of angiogenic factors. VEGF expression in SSc bone marrow is high in all cases with a double median rate compared to controls (48,75% vs 4,25%) while MVD is lower in sclerosis than controls (712,63 vs 1364,58). In regard to these alterations in our study we have observed a reduction of KDR and MMP-9. The overproduction of VEGF can generate a negative feedback to KDR while the low levels of MMP9 found in SSc bone marrow may be due to a hyperproduction of MMP inhibitors contributing to the reduction of bone marrow vascularity. In conclusion, our data demonstrate that in SSc the angiogenic potential of bone marrow is reduced, mirroring the systemic microvascular condition characterised by loss of capillaries and desertification despite the increase of VEGF. The amount of reticular fibers, detected in bone marrow, suggests that the fibrotic process may affect also the bone marrow contributing further to the reduction of angiogenic potential. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2009
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    In: Leukemia Research, Elsevier BV, Vol. 36, No. 2 ( 2012-02), p. 182-185
    Type of Medium: Online Resource
    ISSN: 0145-2126
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2012
    detail.hit.zdb_id: 2008028-1
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    In: Hematological Oncology, Wiley, Vol. 25, No. 4 ( 2007-12), p. 198-203
    Type of Medium: Online Resource
    ISSN: 0278-0232 , 1099-1069
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2007
    detail.hit.zdb_id: 2001443-0
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 110, No. 11 ( 2007-11-16), p. 678-678
    Abstract: A 515W 〉 L/K mutation in MPL (MPLmut) has been described in 5–10% of patients (pts) with myelofibrosis (Pikman Y, PloS Med 2006), possibly associated with JAK2617V 〉 F allele. Among 217 subjects with primary myelofibrosis, the 18 MPLmut pts presented a more severe anemic phenotype than MPL wild-type (MPLWT) pts (Guglielmelli P, BJH 2007). MPL 515W 〉 L mutation has been reported also in 4 pts with essential thrombocythemia (ET) (1%) (Pardanani A, Blood 2006). We have collected 13 MPLmut pts in an unselected series of 273 ET pts according to WHO criteria (4.7% of total) to evaluate whether MPL mutation associated with unique clinical characteristics and eventually whether MPLmut ET pts should be re-classified as having WHO pre-fibrotic myelofibrosis. A novel quantitative real-time PCR assay for 515W 〉 L and 515W 〉 K allele in granulocyte DNA has been designed; detection limit was 0.01% for W 〉 L allele and 0.1% for W 〉 K allele. Six pts were 515W 〉 L and seven were 515W 〉 K; 1 pt with W 〉 L and 4 pts with W 〉 K allele had only mutant allele. Mean mutant allele burden was 44(+/−25)% and 59(+/−21)% for W 〉 L and W 〉 K, respectively. Seven MPLmut pts (53%) also harbored JAK2617V 〉 F allele, as compared to 164/260 of MPLWT (63%); they were 2/6 pts with 515W 〉 L and 5/7 with 515W 〉 K. Mean 617V 〉 F allele burden was significantly lower in MPLmut (11+/− 9%) than MPLWT pts (24+/− 17%; P=0.03). There was no difference in age or gender, but median disease duration was longer in MPLmut pts (110 vs 57 months, P=0.001). At diagnosis, platelet count was significantly higher in MPLmut pts (1,113+/− 438x109/L vs 864+/− 302x109/L; P=0.02), while hemoglobin, serum ferritin, LDH level, and leukocyte count were not statistically different. Frequency of pts presenting endogenous erythroid colonies or PRV-1 over-expression was similar among MPLmut (37% and 44%, respectively) or MPLWT pts (48% and 43%). There was no difference in splenomegaly, systemic symptoms, major thrombosis (30% vs 21%) or hemorrhages (8% vs 6%) between MPLmut and MPLWT pts. However, pts with microvessel disease were significantly more frequent among MPLmut (77% vs 34%, P=0.002). Bone marrow (BM) biopsy at diagnosis of MPLmut pts was reviewed in a blinded fashion among 30 random biopsies from MPLWT ET pts. There was no significant difference in total cellularity, erythoid or myeloid lineage beteween MPLWT and MPLmut pts. Megakaryocyte hyperplasia was prominent in MPLmut pts, with Mks being either scattered or in loose clusters similarly to MPLWT pts. However, in addition to typical large Mks, MPLmut pts displayed a discrete number of small-size vWF and/or CD61-pos Mks. BM fibrosis quantification (revised EUMNET criteria) revealed grade 0–1 fibrosis in all but one MPLmut pts, who presented grade 1–2. Finally, there was no evidence of leukoerythroblastosis in blood smears. One pt died after 11 yrs of major thrombosis, none evolved to myelofibrosis. Overall, these data indicate that prevalence of MPL mutation in ET may be higher (5%) than previously reported, but the mutation per se does not associate with a unique clinical phenotype, a part for a higher platelet count and greater occurrence of microvessel symptoms. Increased number of small-size Mks was observed in BM biopsy, but the whole hystologic pattern, as well as long-term stability of disease, did not support alternative diagnosis of pre-fibrotic myelofibrosis.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages